JP6382801B2 - 細菌感染症の処置のためのテイラーメードされたリポソーム - Google Patents

細菌感染症の処置のためのテイラーメードされたリポソーム Download PDF

Info

Publication number
JP6382801B2
JP6382801B2 JP2015516609A JP2015516609A JP6382801B2 JP 6382801 B2 JP6382801 B2 JP 6382801B2 JP 2015516609 A JP2015516609 A JP 2015516609A JP 2015516609 A JP2015516609 A JP 2015516609A JP 6382801 B2 JP6382801 B2 JP 6382801B2
Authority
JP
Japan
Prior art keywords
sphingomyelin
liposomes
mixture
cholesterol
empty liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015516609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519383A5 (enExample
JP2015519383A (ja
Inventor
ベビーチャック，エドゥアルド
ドレーゲル，アネット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bern
Original Assignee
University of Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bern filed Critical University of Bern
Publication of JP2015519383A publication Critical patent/JP2015519383A/ja
Publication of JP2015519383A5 publication Critical patent/JP2015519383A5/ja
Application granted granted Critical
Publication of JP6382801B2 publication Critical patent/JP6382801B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2015516609A 2012-06-14 2013-06-13 細菌感染症の処置のためのテイラーメードされたリポソーム Active JP6382801B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12171924.9 2012-06-14
EP12171924 2012-06-14
EP13153039.6 2013-01-29
EP13153039 2013-01-29
PCT/EP2013/062207 WO2013186286A1 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018145681A Division JP6656321B2 (ja) 2012-06-14 2018-08-02 細菌感染症の処置のためのテイラーメードされたリポソーム

Publications (3)

Publication Number Publication Date
JP2015519383A JP2015519383A (ja) 2015-07-09
JP2015519383A5 JP2015519383A5 (enExample) 2017-11-16
JP6382801B2 true JP6382801B2 (ja) 2018-08-29

Family

ID=48703423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015516609A Active JP6382801B2 (ja) 2012-06-14 2013-06-13 細菌感染症の処置のためのテイラーメードされたリポソーム
JP2018145681A Active JP6656321B2 (ja) 2012-06-14 2018-08-02 細菌感染症の処置のためのテイラーメードされたリポソーム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018145681A Active JP6656321B2 (ja) 2012-06-14 2018-08-02 細菌感染症の処置のためのテイラーメードされたリポソーム

Country Status (19)

Country Link
US (4) US10744089B2 (enExample)
EP (2) EP2861214B1 (enExample)
JP (2) JP6382801B2 (enExample)
CN (2) CN104602672B (enExample)
AU (2) AU2013276565B2 (enExample)
BR (1) BR112014031278B1 (enExample)
CA (1) CA2875470C (enExample)
CY (1) CY1123337T1 (enExample)
DK (1) DK2861214T3 (enExample)
ES (1) ES2821502T3 (enExample)
HR (1) HRP20201761T1 (enExample)
HU (1) HUE051761T2 (enExample)
LT (1) LT2861214T (enExample)
PL (1) PL2861214T3 (enExample)
RS (1) RS60951B1 (enExample)
RU (1) RU2672106C2 (enExample)
SI (1) SI2861214T1 (enExample)
SM (1) SMT202000584T1 (enExample)
WO (1) WO2013186286A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861214B1 (en) 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
CA3009119A1 (en) 2015-12-28 2017-07-06 Mb Biotech Ltd. Liposomes for treatment of an autoimmune disease
WO2017177073A1 (en) * 2016-04-07 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use
DK3471732T3 (da) 2016-06-16 2020-08-17 Combioxin Sa Liposomer til behandling af virusinfektioner
ES3060425T3 (en) 2017-03-02 2026-03-26 Combioxin Sa Liposomes for inhibiting biofilm formation
US11344497B1 (en) * 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
KR102915698B1 (ko) * 2018-04-17 2026-01-28 콤비옥신 에스에이 폐렴의 치료
PT3781210T (pt) * 2018-04-20 2024-10-02 Combioxin Sa Tratamento da hipotensão com sépsis ou choque séptico
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
EP4093458A4 (en) 2020-01-20 2024-01-17 Arytha Biosciences LLC Devices containing cellular membrane and uses thereof
JP2023536833A (ja) * 2020-07-31 2023-08-30 サインパス ファルマ，インク． サイトカイン放出及びサイトカインストームの抑制
CN115054577B (zh) * 2022-05-17 2024-06-21 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 纳米解毒剂及其在中和mrsa穿孔毒素的应用
WO2026099472A1 (en) 2024-11-08 2026-05-15 Universität Bern Liposomal compositions for treatment of inflammation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641247A (en) 1970-12-14 1972-02-08 Stanley Drug Products Inc Methods of treating bacterial infections
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
NL9000207A (enExample) * 1990-01-29 1991-08-16 Duphar Int Res
WO1993004672A1 (en) * 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
JP4187249B2 (ja) 2002-03-08 2008-11-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 プレシナプス蛋白ｐ１２０
AU2003265241A1 (en) * 2002-05-23 2003-12-12 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
WO2004087097A2 (en) * 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US20090186073A1 (en) 2005-08-11 2009-07-23 National Institute Of Advanced Industrial Science And Technology Design of Delivery Vehicle Based On Rolling Model
CN1939340A (zh) * 2005-09-29 2007-04-04 中国人民解放军军事医学科学院毒物药物研究所 脂质体制剂
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US9637515B2 (en) * 2006-11-06 2017-05-02 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
CN101623262B (zh) * 2009-08-24 2011-02-02 海南美大制药有限公司 一种五水头孢唑啉钠前体脂质体制剂
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
WO2012021107A2 (en) * 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
CN102327220B (zh) * 2011-07-14 2012-09-26 海南灵康制药有限公司 一种氯雷他定脂质体固体制剂
EP2861214B1 (en) 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections
US10716756B2 (en) 2016-06-20 2020-07-21 Vivacelle Bio, Inc. Compositions and methods for reducing reperfusion injury
ES3060425T3 (en) 2017-03-02 2026-03-26 Combioxin Sa Liposomes for inhibiting biofilm formation
KR102915698B1 (ko) 2018-04-17 2026-01-28 콤비옥신 에스에이 폐렴의 치료

Also Published As

Publication number Publication date
US10744089B2 (en) 2020-08-18
RS60951B1 (sr) 2020-11-30
US20230031648A1 (en) 2023-02-02
JP6656321B2 (ja) 2020-03-04
BR112014031278B1 (pt) 2020-12-01
AU2013276565A1 (en) 2014-12-18
LT2861214T (lt) 2020-12-28
PL2861214T3 (pl) 2021-02-08
DK2861214T3 (da) 2020-10-12
EP3782606A1 (en) 2021-02-24
RU2018138012A (ru) 2019-03-21
CN104602672A (zh) 2015-05-06
AU2013276565B2 (en) 2018-12-20
CA2875470A1 (en) 2013-12-19
US20150157570A1 (en) 2015-06-11
US20220087934A1 (en) 2022-03-24
AU2019201776B2 (en) 2020-11-12
CA2875470C (en) 2021-01-12
US20200345639A1 (en) 2020-11-05
CN104602672B (zh) 2018-12-25
RU2014148284A (ru) 2016-08-10
HK1210018A1 (en) 2016-04-15
HRP20201761T1 (hr) 2020-12-25
SI2861214T1 (sl) 2021-01-29
ES2821502T3 (es) 2021-04-26
EP2861214B1 (en) 2020-08-05
EP2861214A1 (en) 2015-04-22
CN109549925B (zh) 2022-06-17
HUE051761T2 (hu) 2021-03-29
CN109549925A (zh) 2019-04-02
JP2018184470A (ja) 2018-11-22
JP2015519383A (ja) 2015-07-09
BR112014031278A2 (pt) 2017-06-27
SMT202000584T1 (it) 2020-11-10
RU2672106C2 (ru) 2018-11-12
CY1123337T1 (el) 2021-12-31
AU2019201776A1 (en) 2019-04-04
WO2013186286A1 (en) 2013-12-19
US12599558B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
US12599558B2 (en) Tailored liposomes for the treatment of bacterial infections
JP5918922B2 (ja) 脂質を用いた薬物製剤の高速送達とその処置方法
CN107072944B (zh) 具有抗非结核分枝杆菌活性的脂质体环丙沙星制剂
KR100438657B1 (ko) 저치밀성리포솜항균조성물
Diab et al. Insights in nanoparticle-bacterium interactions: new frontiers to bypass bacterial resistance to antibiotics
CN101511430A (zh) 抗生素组合物
AU2025201451A1 (en) Treatment of pneumonia
Isayenko Synergistic activity of filtrates of Lactobacillus rhamnosus and Saccharomyces boulardii and antibacterial preparations against Corynebacterium spp.
RU2780026C2 (ru) Специально разработанные липосомы для лечения бактериальных инфекций
HK40046902A (en) Tailored liposomes for the treatment of bacterial infections
HK1210018B (en) Tailored liposomes for the treatment of bacterial infections
US20210007985A1 (en) Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm
Esparza Thiostrepton in phospholipid micelles: development of scalable production method and in vivo evaluation
Ferreira Antibiotic-lipid based nanosystem as a tool to specifically target Staphylococcus aureus biofilms
Gbian Modulation of antimicrobial activity by liposomal antibiotics for the treatment of Pseudomonas aeruginosa isolated from cystic fibrosis patients: potential role of the efflux pump inhibitor Phenylalanine Arginine-β-Naphthylamide
Alhariri Evaluation of liposomal bismuth-ethanedithiol-tobramycin for treatment of cystic fibrosis pulmonary pseudomonas aeruginosa infection

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170904

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20171004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180802

R150 Certificate of patent or registration of utility model

Ref document number: 6382801

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250